AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03652740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects of commonly used medications on mood and medication preference
Description: Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States.
Study NCT02336594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Study NCT00669656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostate Health Cocktail
Description: 3 capsules daily PO up 12 months
Study NCT00415168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
Study NCT00415168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, IV, every 21 days x 6 cycles
Study NCT03622814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners at Meals
Description: The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
Study NCT03622814 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Condition
Description: Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
Study NCT03523130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Macrophage-specific inflammation
Study NCT02858960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen
Description: Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
Study NCT02858960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Venturi Mask
Description: Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
Study NCT02197429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT03855137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant 30 mg
Description: Tablets containing 30 mg atogepant
Study NCT03855137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant 60 mg
Description: Tablets containing 60 mg atogepant
Study NCT03855137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 30 mg/60 mg tablets containing atogepant-matching placebo
Study NCT03855137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg/60 mg tablets containing atogepant-matching placebo
Study NCT02651194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study NCT01212172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soprano/SHR
Description: For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
Study NCT01212172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LightSheer
Description: The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
Study NCT00966758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: 1 low dose CT scan is taken
Study NCT00966758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Photon Emission Computed Tomography
Description: 1 SPECT scan is taken
Study NCT03482219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home app intervention
Description: The app consists of videos depicting each exercise and ability to track adherence to exercises.
Study NCT06490406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (communication and education simulations) for EG1
Description: In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices.
Study NCT01745952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: figure-of-eight active rTMS coil
Description: navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
Study NCT01745952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: round active rTMS coil
Description: navigated rTMS over epileptogenic focus using round active rTMS coil
Study NCT01745952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS coil (figure-of-eight)
Description: commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
Study NCT02972021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Study NCT03056040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Study NCT03056040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Study NCT02972021 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-flow nasal cannula
Study NCT02788513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 1
Study NCT02788513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 2
Study NCT02788513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 3
Study NCT02788513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 dose 4
Study NCT02788513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03056040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
Study NCT04163523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Study NCT04799405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day.
Study NCT01687738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication intervention
Description: Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
Study NCT01687738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Time Registry and data feedback only
Description: This group of patients will not received the enhanced communication intervention
Study NCT03982771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: -Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
Study NCT03982771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
Study NCT00610688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenatal Vitamin
Description: Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
Study NCT00610688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal Vitamin
Description: Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
Study NCT00610688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
Study NCT00610688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
Study NCT02228408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine/Isorsorbide Dinitrate
Description: Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects.
Study NCT02228408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo titration will mimic titration of active study arm
Study NCT00819442 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cardiobiopsy
Description: 5 samples will be taken from right ventricle by Cordis bioptome
Study NCT02418078 — intervention group
Intervention type: PROCEDURE
Intervention: local infiltration anesthesia and sedation
Description: the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
Study NCT03098121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grazoprevir and elbasvir
Description: For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
Study NCT02918201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: TXA 25 mg/ml applied topically to moisten the wound
Study NCT00819442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiobiopsy
Description: 5 samples will be taken from right ventricle by Cordis bioptome
Study NCT03982771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethason
Description: Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
Study NCT02196051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one bout of 45 minutes exercise
Description: 45 minutes of exercise on an elliptical exercise machine
Study NCT02918201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline solution (0.9% NaCl) applied topically to moisten the wound
Study NCT00657358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
Study NCT02481583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosulpiride
Description: different formulations of levosulpiride
Study NCT03596008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active drink
Description: The freeze-dried strawberry powder (25 g) in active drink
Study NCT03596008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink
Study NCT04862117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.
Study NCT02444819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: HM61713 will be administered to evaluate efficacy and safety of subjects.
Study NCT02413125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChitoRhino irrigation solution
Description: ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
Study NCT02413125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
Study NCT03631875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
Study NCT03631875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
Study NCT02270008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor training
Description: Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
Study NCT02326792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
Study NCT02364726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
Study NCT02364726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropathic Pain Scale (NPS) questionnaire
Description: It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
Study NCT02364726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT/GOG-Ntx questionnaire
Description: It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
Study NCT01742000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Karinat
Study NCT01742000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Study NCT03941405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin treatment
Description: one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
Study NCT04279912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis
Description: The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
Study NCT00788775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT04629989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oxygen Delivery System
Description: The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
Study NCT04629989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double-Trunk Mask
Description: The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
Study NCT04629989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical Mask
Description: The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
Study NCT02481037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care clinical pathway
Description: Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
Study NCT02481037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma education
Description: Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
Study NCT02481037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR embedded dashboard
Description: An EMR embedded dashboard will deliver real-time feedback to clinicians.
Study NCT04584970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applied VR
Description: The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
Study NCT04584970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple iPad
Description: The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
Study NCT01790854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel dose 5 mg/day
Study NCT01613287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSorb® - Ig flex
Description: TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days.
Study NCT02708043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flexible-Laryngeal Mask Airway